Kornelius Schulze
Overview
Explore the profile of Kornelius Schulze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
2647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gairing S, Mildenberger P, Gile J, Artusa F, Scheiner B, Leyh C, et al.
JHEP Rep
. 2025 Mar;
7(3):101295.
PMID: 40059970
Background & Aims: Immunotherapy with atezolizumab and bevacizumab (a + b) has improved the prognosis of patients with unresectable hepatocellular carcinoma (HCC). However, the outcome for individual patients is highly...
2.
Wu M, Fulgenzi C, DAlessio A, Cortellini A, Celsa C, Manfredi G, et al.
JHEP Rep
. 2025 Jan;
7(2):101232.
PMID: 39877031
Background & Aims: Atezolizumab/bevacizumab (A/B) is now a standard first-line treatment for advanced hepatocellular carcinoma (HCC), but the optimal second-line regimen is not known. We evaluated real-world treatment patterns and...
3.
Scheiner B, Kang B, Balcar L, Radu I, Reiter F, Adzic G, et al.
Hepatology
. 2024 Dec;
PMID: 39643944
Background And Aims: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)-based systemic therapies is unclear. Approach And Results: Retrospective study of patients with...
4.
Gorgulho J, Loosen S, Masood R, Giehren F, Pagani F, Buescher G, et al.
J Exp Clin Cancer Res
. 2024 Nov;
43(1):298.
PMID: 39511626
Background: The major breakthrough in cancer therapy with immune checkpoint inhibitors (ICIs) has highlighted the important role of immune checkpoints in antitumoral immunity. However, most patients do not achieve durable...
5.
Mitzlaff K, Kirstein M, Muller C, Venerito M, Olkus A, Dill M, et al.
United European Gastroenterol J
. 2024 Sep;
12(9):1230-1242.
PMID: 39301763
Background: Combined Immuno-chemotherapy consisting of gemcitabine, cisplatin and the programmed death-ligand one inhibitor durvalumab (GCD) is the new standard of care for patients with biliary tract cancers (BTC) based on...
6.
Stern L, Schmidt C, Kocheise L, Joerg V, Casar C, Walter A, et al.
Ann Hepatol
. 2024 Aug;
29(6):101534.
PMID: 39147132
Introduction And Objectives: Autoimmune liver diseases (AILD) are rare causes hepatocellular carcinoma (HCC), and data on the efficacy and tolerability of anti-tumor therapies are scarce. This pan-European study aimed to...
7.
Schmidt C, Zapf A, Ozga A, Canbay A, Denzer U, De Toni E, et al.
BMC Cancer
. 2024 Aug;
24(1):931.
PMID: 39090600
Background: Despite the recent advances in cancer treatment, the therapeutic options for patients with biliary tract cancer are still very limited and the prognosis very poor. More than 50% of...
8.
Celsa C, Cabibbo G, Fulgenzi C, Battaglia S, Enea M, Scheiner B, et al.
Hepatology
. 2024 Jul;
81(3):837-852.
PMID: 39028886
Background And Aims: Unlike other malignancies, hepatic functional reserve competes with tumor progression in determining the risk of mortality from hepatocellular carcinoma (HCC). However, the relative contribution of hepatic decompensation...
9.
Fulgenzi C, Scheiner B, DAlessio A, Mehan A, Manfredi G, Celsa C, et al.
JAMA Oncol
. 2024 Jul;
10(9):1253-1258.
PMID: 39023864
Importance: Whether patients with Child-Pugh class B (CP-B) cancer with unresectable hepatocellular carcinoma (uHCC) benefit from active anticancer treatment vs best supportive care (BSC) is debated. Objective: To evaluate the...
10.
Kocheise L, Piseddu I, Vonderlin J, Tjwa E, Buescher G, Meunier L, et al.
Front Immunol
. 2024 Feb;
15:1369747.
PMID: 38327519
[This corrects the article DOI: 10.3389/fimmu.2023.1326078.].